Improved Treatment for Head and Neck Cancer with 5-FU Monitoring
Author Information
Author(s): J. Santini, G. Milano, A. Thyss, N. Renee, P. Viens, P. Ayela, M. Schneider, F. Demard
Primary Institution: Centre Antoine Lacassagne
Hypothesis
Can therapeutic monitoring of 5-FU improve treatment outcomes in head and neck cancer?
Conclusion
Real-time monitoring and dose adjustment of 5-FU significantly improved treatment response and reduced toxicity in head and neck cancer patients.
Supporting Evidence
- Patients receiving monitored doses had a higher complete response rate (47%) compared to those who did not (31%).
- Toxic cycles were reduced from 20% in the first group to 12.4% in the second group.
- Pharmacokinetic monitoring allowed for dose adjustments in 40% of cycles.
Takeaway
Doctors can make better decisions about cancer treatment by checking how much medicine is in the body, which helps patients feel better and have fewer side effects.
Methodology
The study involved a retrospective analysis of 177 cycles in 77 patients followed by a prospective study with real-time dose adjustments based on pharmacokinetic data.
Limitations
The study may have variability in patient responses and the sample size for some analyses was limited.
Participant Demographics
145 men and 25 women, mean age 61 years (range 36-82).
Statistical Information
P-Value
0.02
Statistical Significance
0.02<P<0.05
Want to read the original?
Access the complete publication on the publisher's website